RT Journal Article
SR Electronic
T1 Effectiveness of Four Vaccines in Preventing SARS-CoV-2 Infection in Kazakhstan
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.14.22273868
DO 10.1101/2022.04.14.22273868
A1 Nabirova, Dilyara
A1 Horth, Roberta
A1 Smagul, Manar
A1 Nukenova, Gaukhar
A1 Yesmagambetova, Aizhan
A1 Singer, Daniel
A1 Henderson, Alden
A1 Tsoy, Alexey
YR 2022
UL http://medrxiv.org/content/early/2022/04/18/2022.04.14.22273868.abstract
AB BACKGROUND In February 2021 Kazakhstan began offering COVID-19 vaccines to adults. Breakthrough SARS-CoV-2 infections raised concerns about real-world vaccine effectiveness. We aimed to evaluate effectiveness of four vaccines against SARS-CoV-2 infection.METHODS We conducted a retrospective cohort analysis among adults in Almaty using aggregated vaccination data and individual-level breakthrough COVID-19 cases (≥14 days from 2nd dose) using national surveillance data. We ran time-adjusted Cox-proportional-hazards model with sensitivity analysis accounting for varying entry into vaccinated cohort to assess vaccine effectiveness for each vaccine (measured as 1-adjusted hazard ratios) using the unvaccinated population as reference (N=565,390). We separately calculated daily cumulative hazards for COVID-19 breakthrough among vaccinated persons by age and vaccine month.RESULTS From February 22 to Sept 1, 2021 in Almaty, 747,558 (57%) adults were fully vaccinated (received 2 doses) and 108,324 COVID-19 cases (11,472 breakthrough) were registered. Vaccine effectiveness against infection was 78% (sensitivity estimates: 74–82%) for QazVac, 77% (72– 81%) for Sputnik V, 71% (69–72%) for Hayat-Vax, and 69% (64–72%) for CoronaVac. Among vaccinated persons, the 90-day follow-up cumulative hazard for breakthrough infection was 2.2%. Cumulative hazard was 2.9% among people aged ≥60 years versus 1.9% among persons aged 18–39 years (p<0.001), and 1.2% for people vaccinated in February–May versus 3.3% in June–August (p<0.001).CONCLUSION Our analysis demonstrates high effectiveness of COVID-19 vaccines against infection in Almaty similar to other observational studies. Higher cumulative hazard of breakthrough among people >60 years of age and during variant surges warrants targeted booster vaccination campaigns.What is already known on this topicPlenty of data are published on effectiveness of mRNA vaccines; however, these vaccines were not widely available in many low- and middle-income countries in 2021.There are no real-world effectiveness studies on several vaccines available in the Central Asia region, including QazVac vaccine, an inactivated vaccine developed by Kazakhstan.Understanding how these vaccines are performing outside of clinical trials is critical for the COVID-19 response and lack of published data can contribute to vaccine hesitancy.What this study addsOur study demonstrated that at the population-level the four vaccines against COVID-19 used in Kazakhstan were effective at preventing SARS-CoV-2 infection.Vaccination reduced the risk of infection by 76% and prevented over 100,000 cases of SARS-CoV-2 infection in Almaty, the country’s most populous city.This is also the first study that demonstrated high vaccine effectiveness in real-world conditions of QazVac, developed in Kazakhstan.How this study might affect research, practice or policyPolicy makers in Kazakhstan and the Central Asia region need data on vaccines provided in the region to update evidence-based vaccine guidelines for different populations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was deemed non-research public health activity by the MoH of Kazakhstan and the institutional review board of CDC and conducted in accordance with CDC policy (project ID 0900f3eb81e4b259)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors cannot share individual level data due to the national data protection regulations. Deidentified data might be made available for authorized researchers after application to the Ministry of Healthcare of the Republic of Kazakhstan. The authors confirm that the manuscript is an honest, accurate, and transparent account of the investigation being reported; and that no important aspects of the study have been omitted. Dissemination to participants and related patient and public communities: The Ministry of Healthcare of the Republic of Kazakhstan and the authors will disseminate the study findings through press releases, a website (https://rk-ncph.kz/ru/), and through social media